Viral Encephalitis Medication

Updated: Feb 18, 2016
  • Author: Francisco de Assis Aquino Gondim, MD, PhD, MSc, FAAN; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Medication

Medication Summary

Pharmacotherapy for herpes simplex encephalitis (HSE) consists of acyclovir and vidarabine. Outcome is improved with either agent, but acyclovir is more effective and less toxic. Even if the final diagnosis of HSE has not been established, intravenous (IV) acyclovir should be initiated immediately. Acyclovir is also the drug of choice for varicella-zoster virus (VZV) encephalitis, although ganciclovir is also considered an alternative option.

Ganciclovir has been used for cytomegalovirus (CMV) encephalitis, but with therapeutic failures; optimal therapy for CMV encephalitis is unknown. Ganciclovir combined with foscarnet has been used in the treatment of patients infected with HIV.

No specific treatment is available for the arbovirus encephalitides. The efficacy of ribavirin in other viral infections is being evaluated.

Next:

Antiviral Agents

Class Summary

Antiviral agents shorten the clinical course, prevent complications, prevent development of latency and subsequent recurrences, decrease transmission, and eliminate established latency.

Acyclovir (Zovirax)

Acyclovir has demonstrated inhibitory activity against both herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) and is taken up selectively by infected cells. Before the use of acyclovir, mortality from HSE was 60-70%; since acyclovir, it has been approximately 30%. Acyclovir may also be effective for VZV encephalitis.

Ribavirin (Virazole, Ribasphere)

Ribavirin is a synthetic guanosine analogue (1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) that inhibits viral replication by inhibiting DNA and RNA synthesis. It is phosphorylated in vivo, and the active form may interfere with viral genomic synthesis.

Clinical experience in the treatment of arenavirus infections is primarily with Lassa fever, but anecdotal experience in South American arenaviruses also exists. Ribavirin is used clinically in combination with interferon for hepatitis C, in aerosol form for respiratory syncytial virus (RSV), and as potential prophylaxis and/or treatment of Congo-Crimean hemorrhagic fever, hantavirus infections, and arenavirus hemorrhagic fevers. In vitro evidence exists for activity against West Nile virus.

The IV form of the drug is not readily available, and the manufacturer should be contacted if the need arises.

Ganciclovir (Cytovene, Vitrasert)

Ganciclovir is a synthetic guanine derivative that is active against CMV. It is an acyclic nucleoside analogue of 2'-deoxyguanosine that inhibits viral replication in vitro and in vivo by competing with deoxyguanosine triphosphate for viral DNA polymerase, inhibiting DNA synthesis. Ganciclovir triphosphate levels are up to 100-fold greater in CMV-infected cells than in uninfected cells, possibly because of preferential phosphorylation in infected cells.

Foscarnet (Foscavir)

Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits viral replication in vitro. It exerts its antiviral activity by selective inhibition at pyrophosphate-binding sites on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases, inhibiting DNA synthesis.

Viral resistance should be considered in patients with poor clinical response or persistent viral excretion. Patients who show excellent tolerance of foscarnet may benefit from initiation of a maintenance dosage (ie, 120 mg/kg/d) earlier in their treatment. Individualize the dosing according to the patient's renal function status. Foscarnet has been demonstrated to be effective against CMV encephalitis.

Previous
Next:

Anticonvulsant Agents

Class Summary

These agents prevent seizure recurrence and terminate clinical and electrical seizure activity.

Phenytoin (Dilantin, Phenytek)

Phenytoin may act in the motor cortex, where it may inhibit the spread of seizure activity. The activity of brain stem centers responsible for the tonic phase of grand mal seizures may also be inhibited.

Individualize the dose. Administer a larger dose before retiring if the dose cannot be divided equally. The rate of infusion must not exceed 50 mg per minute to avoid hypotension and arrhythmia.

Diazepam (Valium)

Diazepam depresses all levels of the CNS (eg, limbic, reticular formation), possibly by increasing the activity of gamma-aminobutyric acid (GABA). Alternatively, lorazepam can be used when indicated.

Carbamazepine (Tegretol, Carbatrol, Epitol, Equetro)

Carbamazepine is effective in treatment of complex partial seizures; it appears to act by reducing polysynaptic responses and blocking posttetanic potentiation.

Once a response is attained, attempt to reduce the dose to the minimum effective level or to discontinue the drug at least once every 3 months.

Valproic acid (Depakote, Depakene, Depacon, Stavzor)

Valproic acid is chemically unrelated to other drugs that treat seizure disorders. Although its mechanism of action is not established, its activity may be related to increased brain levels of gamma-aminobutyric acid (GABA) or enhanced GABA action. It also may potentiate postsynaptic GABA responses, affect potassium channels, or have a direct membrane-stabilizing effect.

Previous
Next:

Osmotic Diuretics

Class Summary

Mannitol is recommended by some experts to help reduce intracranial pressure. Mannitol induces diuresis, which increases serum osmotic concentration. In the brain, this causes water to flow from brain cells into vascular space, thereby decreasing intracranial pressure.

Mannitol (Osmitrol, Resectisol)

Mannitol may be used to decrease intracranial pressure. It may reduce subarachnoid space pressure by creating an osmotic gradient between CSF in the arachnoid space and plasma. This agent is not for long-term use.

Initially assess the patient for adequate renal function by administering a test dose of 200 mg/kg intravenously over 3-5 min. It should produce a urine flow of at least 30-50 mL per hour of urine over 2-3 hours.

In children, assess for adequate renal function by administering a test dose of 200 mg/kg intravenously over 3-5 min. It should produce a urine flow of at least 1 mL/kg/h over 1-3 hours.

Previous